Temozolomide in the treatment of recurrent malignant glioma

摘要: BACKGROUND Options for chemotherapy at the time of recurrence in patients with malignant glioma are limited. The authors describe efficacy and safety results their institution's open-label, compassionate-use protocol temozolomide recurrent glioma. METHODS Patients any during were treated oral a dose pf 150 mg/m2 per day on 5-day schedule every 28 days. If this was tolerated, then escalation to 200 allowed. Clinical evaluations assessments tumor response performed 2 months. All or surrogates signed approved Institutional Review Board consent forms. RESULTS Among 213 who treated, 33% had Grade 3 tumors, 67% 4 tumors. overall objective rate 16% both these patient groups; an additional 51% 30% respectively, stable disease as best response. 6-month progression-free survival rates 41% 18% respectively. median 49 weeks tumors 32 major toxicity hematologic toxicity. In multivariate analysis, Karnofsky performance score significant predictor tumors. CONCLUSIONS Temozolomide well tolerated modest efficacy, even multiple recurrences. Cancer 2004. © 2003 American Society.